OBJECTIVES: Kaposi sarcoma (KS) is one of the most common childhood cancers in eastern and central Africa. It has become a treatable disease with increasing availability of antiretroviral therapy (ART) and chemotherapy. We aimed to fill the data gap in establishing whether long-term survival is achievable for children in low-income countries. METHODS: We retrospectively analysed data for children and adolescents aged ≤ 18.9 years diagnosed with HIV-related or endemic KS from 2006 to 2015 who received standardized institutional treatment regimens utilizing chemotherapy plus ART (if HIV-positive) at a tertiary care public hospital in Lilongwe, Malawi. Long-term survival was analysed and mortality was associated with KS for those with refractory/progressive disease at the time of death. RESULTS: There were 207 children/adolescents with KS (90.8% HIV-related); 36.7% were alive, 54.6% had died, and 8.7% had been lost to follow-up. The median follow-up time for survivors was 6.9 years (range 4.2-13.9 years). Death occurred at a median of 5.3 months after KS diagnosis (range 0.1-123 months). KS progression was associated with mortality for most (61%) early deaths (survival time of < 6 months); conversely, KS was associated with a minority (31%) of late-onset deaths (after 24 months). The 7-year overall survival was 37% [95% confidence interval (CI) 30-44%] and was higher for those diagnosed between 2011 and 2015 compared to 2006-2010: 42% (95% CI 33-51%) versus 29% (95% CI 20-39%), respectively (P = 0.01). Among the 66 HIV-positive survivors, 58% were still on first-line ART. CONCLUSIONS: Long-term survival is possible for pediatric KS in low-resource settings. Despite better survival in more recent years, there remains room for improvement.
OBJECTIVES: Kaposi sarcoma (KS) is one of the most common childhood cancers in eastern and central Africa. It has become a treatable disease with increasing availability of antiretroviral therapy (ART) and chemotherapy. We aimed to fill the data gap in establishing whether long-term survival is achievable for children in low-income countries. METHODS: We retrospectively analysed data for children and adolescents aged ≤ 18.9 years diagnosed with HIV-related or endemic KS from 2006 to 2015 who received standardized institutional treatment regimens utilizing chemotherapy plus ART (if HIV-positive) at a tertiary care public hospital in Lilongwe, Malawi. Long-term survival was analysed and mortality was associated with KS for those with refractory/progressive disease at the time of death. RESULTS: There were 207 children/adolescents with KS (90.8% HIV-related); 36.7% were alive, 54.6% had died, and 8.7% had been lost to follow-up. The median follow-up time for survivors was 6.9 years (range 4.2-13.9 years). Death occurred at a median of 5.3 months after KS diagnosis (range 0.1-123 months). KS progression was associated with mortality for most (61%) early deaths (survival time of < 6 months); conversely, KS was associated with a minority (31%) of late-onset deaths (after 24 months). The 7-year overall survival was 37% [95% confidence interval (CI) 30-44%] and was higher for those diagnosed between 2011 and 2015 compared to 2006-2010: 42% (95% CI 33-51%) versus 29% (95% CI 20-39%), respectively (P = 0.01). Among the 66 HIV-positive survivors, 58% were still on first-line ART. CONCLUSIONS: Long-term survival is possible for pediatric KS in low-resource settings. Despite better survival in more recent years, there remains room for improvement.
Authors: Mina C Hosseinipour; Minhee Kang; Susan E Krown; Aggrey Bukuru; Triin Umbleja; Jeffrey N Martin; Jackson Orem; Catherine Godfrey; Brenda Hoagland; Noluthando Mwelase; Deborah Langat; Mulinda Nyirenda; John MacRae; Margaret Borok; Wadzanai Samaneka; Agnes Moses; Rosie Mngqbisa; Naftali Busakhala; Otoniel Martínez-Maza; Richard Ambinder; Dirk P Dittmer; Mostafa Nokta; Thomas B Campbell Journal: Clin Infect Dis Date: 2018-07-02 Impact factor: 9.079
Authors: Christopher C Stanley; Kate D Westmoreland; Salama Itimu; Ande Salima; Toon van der Gronde; Peter Wasswa; Idah Mtete; Mercy Butia; Nader K El-Mallawany; Satish Gopal Journal: Pediatr Blood Cancer Date: 2016-11-28 Impact factor: 3.167
Authors: Mark Bower; Alessia Dalla Pria; Chris Coyle; Eileen Andrews; Victoria Tittle; Sharanjit Dhoot; Mark Nelson Journal: J Clin Oncol Date: 2013-12-30 Impact factor: 44.544
Authors: Nader Kim El-Mallawany; William Kamiyango; Jeremy S Slone; Jimmy Villiera; Carrie L Kovarik; Carrie M Cox; Dirk P Dittmer; Saeed Ahmed; Gordon E Schutze; Michael E Scheurer; Peter N Kazembe; Parth S Mehta Journal: PLoS One Date: 2016-04-15 Impact factor: 3.240
Authors: Nader Kim El-Mallawany; William Kamiyango; Jimmy Villiera; Jeremy S Slone; Carrie L Kovarik; Liane R Campbell; Anurag K Agrawal; Dirk P Dittmer; Anthony B Eason; Saeed Ahmed; Gordon E Schutze; Michael E Scheurer; Peter N Kazembe; Parth S Mehta Journal: J Glob Oncol Date: 2017-12-22
Authors: Nader Kim El-Mallawany; Jimmy Villiera; William Kamiyango; Erin C Peckham-Gregory; Michael E Scheurer; Carl E Allen; Casey L McAtee; Alejandra Legarreta; Dirk P Dittmer; Carrie L Kovarik; Elizabeth Y Chiao; Stephen C Martin; Nmazuo W Ozuah; Parth S Mehta; Peter N Kazembe Journal: Infect Agent Cancer Date: 2018-11-09 Impact factor: 2.965
Authors: Corey Casper; Lawrence Corey; Jeffrey I Cohen; Blossom Damania; Anne A Gershon; David C Kaslow; Laurie T Krug; Jeffrey Martin; Sam M Mbulaiteye; Edward S Mocarski; Patrick S Moore; Javier Gordon Ogembo; Warren Phipps; Denise Whitby; Charles Wood Journal: NPJ Vaccines Date: 2022-09-20 Impact factor: 9.399